DE60226710D1 - Kombination von docetaxel mit flavopiridol - Google Patents

Kombination von docetaxel mit flavopiridol

Info

Publication number
DE60226710D1
DE60226710D1 DE60226710T DE60226710T DE60226710D1 DE 60226710 D1 DE60226710 D1 DE 60226710D1 DE 60226710 T DE60226710 T DE 60226710T DE 60226710 T DE60226710 T DE 60226710T DE 60226710 D1 DE60226710 D1 DE 60226710D1
Authority
DE
Germany
Prior art keywords
flavopiridol
docetaxel
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60226710T
Other languages
German (de)
English (en)
Inventor
Marie-Christine Bissery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of DE60226710D1 publication Critical patent/DE60226710D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60226710T 2001-03-23 2002-03-22 Kombination von docetaxel mit flavopiridol Expired - Lifetime DE60226710D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27794801P 2001-03-23 2001-03-23
US30269201P 2001-07-05 2001-07-05
US33491601P 2001-12-04 2001-12-04
PCT/EP2002/004083 WO2002076484A2 (en) 2001-03-23 2002-03-22 Combination of a taxane and a cyclin-dependent kinase inhibitor

Publications (1)

Publication Number Publication Date
DE60226710D1 true DE60226710D1 (de) 2008-07-03

Family

ID=27402954

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60226710T Expired - Lifetime DE60226710D1 (de) 2001-03-23 2002-03-22 Kombination von docetaxel mit flavopiridol

Country Status (33)

Country Link
US (2) US20020182204A1 (enExample)
EP (1) EP1372652B1 (enExample)
JP (1) JP2004521140A (enExample)
KR (1) KR100879712B1 (enExample)
CN (1) CN1498107A (enExample)
AR (1) AR034222A1 (enExample)
AT (1) ATE395917T1 (enExample)
AU (1) AU2002312815B2 (enExample)
BR (1) BR0208221A (enExample)
CA (1) CA2441441C (enExample)
CY (1) CY1110449T1 (enExample)
CZ (1) CZ301423B6 (enExample)
DE (1) DE60226710D1 (enExample)
DK (1) DK1372652T3 (enExample)
EA (1) EA007815B1 (enExample)
ES (1) ES2305253T3 (enExample)
HR (1) HRPK20030766B3 (enExample)
HU (1) HU229258B1 (enExample)
IL (2) IL158058A0 (enExample)
ME (1) MEP16408A (enExample)
MX (1) MXPA03007743A (enExample)
NO (1) NO332441B1 (enExample)
NZ (1) NZ527655A (enExample)
PE (1) PE20020907A1 (enExample)
PL (1) PL206118B1 (enExample)
PT (1) PT1372652E (enExample)
RS (1) RS50681B (enExample)
SI (1) SI1372652T1 (enExample)
SK (1) SK287481B6 (enExample)
TW (1) TWI355935B (enExample)
UY (1) UY27220A1 (enExample)
WO (1) WO2002076484A2 (enExample)
ZA (1) ZA200307381B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003217982A1 (en) * 2002-03-06 2003-09-22 The Medical Research And Education Trust Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising wogonin, isoliquiritigenin and/or coumestrol
AU2003287081A1 (en) * 2002-10-16 2004-05-04 Ilex Products, Inc. Clofarabine and taxane chemotherapy combination
EP1558242B1 (en) * 2002-11-06 2008-12-24 Cyclacel Limited Combination comprising docetaxel and a cdk inhibitor
ES2390237T3 (es) * 2006-02-10 2012-11-07 Nerviano Medical Sciences S.R.L. Combinaciones que comprenden un inhibidor de cdk y un anticuerpo anti-factor de crecimiento o un agente antimitótico
BR112013012313A2 (pt) * 2010-11-19 2019-09-24 Piramal Enterprises Limited combinação farmacêutica de paclitaxel e um inibidor de cdk
ME03589B (me) 2011-04-01 2020-07-20 Astrazeneca Ab Terapeutski tretman
MX367640B (es) 2011-11-30 2019-08-29 Astrazeneca Ab Tratamiento combinado del cáncer.
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
EP0888458A4 (en) * 1996-02-20 2004-05-06 Sloan Kettering Institutefor C COMBINATION OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCER

Also Published As

Publication number Publication date
NO20034124L (no) 2003-09-16
TWI355935B (en) 2012-01-11
UY27220A1 (es) 2002-09-30
PT1372652E (pt) 2008-07-24
SK11692003A3 (sk) 2004-03-02
ATE395917T1 (de) 2008-06-15
CY1110449T1 (el) 2015-04-29
HUP0303589A2 (hu) 2004-03-01
WO2002076484A3 (en) 2003-01-03
KR100879712B1 (ko) 2009-01-22
MXPA03007743A (es) 2004-11-12
BR0208221A (pt) 2004-03-02
EA007815B1 (ru) 2007-02-27
EP1372652B1 (en) 2008-05-21
IL158058A (en) 2010-02-17
NZ527655A (en) 2006-03-31
RS50681B (sr) 2010-06-30
ZA200307381B (en) 2005-03-30
CA2441441C (en) 2009-05-26
KR20030086318A (ko) 2003-11-07
JP2004521140A (ja) 2004-07-15
PL206118B1 (pl) 2010-07-30
HUP0303589A3 (en) 2007-05-02
US20060128640A1 (en) 2006-06-15
CN1498107A (zh) 2004-05-19
SI1372652T1 (sl) 2008-10-31
YU69503A (sh) 2006-08-17
US20020182204A1 (en) 2002-12-05
PL367702A1 (en) 2005-03-07
CA2441441A1 (en) 2002-10-03
EA200301053A1 (ru) 2004-02-26
ES2305253T3 (es) 2008-11-01
SK287481B6 (sk) 2010-11-08
DK1372652T3 (da) 2008-09-22
CZ20032551A3 (en) 2004-07-14
HRPK20030766B3 (en) 2006-11-30
NO20034124D0 (no) 2003-09-16
PE20020907A1 (es) 2002-12-19
NO332441B1 (no) 2012-09-17
HRP20030766A2 (en) 2005-06-30
EP1372652A2 (en) 2004-01-02
HU229258B1 (en) 2013-10-28
AU2002312815B2 (en) 2006-08-24
CZ301423B6 (cs) 2010-02-24
MEP16408A (en) 2010-10-10
AR034222A1 (es) 2004-02-04
WO2002076484A2 (en) 2002-10-03
IL158058A0 (en) 2004-03-28

Similar Documents

Publication Publication Date Title
EP1412378A4 (en) APTAMERS AND ANTIAPTAMERS
DE60230173D1 (de) Presbyopiekorrektur
EP1298180A4 (en) HYDROPHOBIC AND LIPOPHOBE COMPOSITION
DK1671949T3 (da) Substituerede pyridinylaminer
NO20014084D0 (no) Dypbronnsinstrumentering
PL370109A1 (pl) Sposoby rozsyłania grupowego treści
DE50212455D1 (de) Verwendung von Dimerdiolen
ATE335486T1 (de) Hydrazono-malonitrile
ATE428695T1 (de) Spirocyclische 3-phenyl-3-substituierte-4- ketolaktame und -laktone
DE60220342D1 (de) Reifenlaufflächdüse
ATE355059T1 (de) Isoxazolopyridinone
DE60123416D1 (de) Refiner
ATE435197T1 (de) Substituierte 4-aminocyclohexanole
ATE395917T1 (de) Kombination von docetaxel mit flavopiridol
DE60234481D1 (de) Verschachtelungsverfahren
DE60007360T2 (de) Amorphe modifikation von torasemid
ATA18372001A (de) Gelenksbolzenbaueinheit
ATE299873T1 (de) Substituierte c-furan-2-yl-methylamin- und c- thiophen-2-yl-methylamin-derivate
DE50211807D1 (de) Schiebernadel
DE60219418T8 (de) Silanylphenole und -naphthole
DE50209548D1 (de) Substituierte 1-aryl-but-3-enylamin- und 1-aryl-but-2-enylaminverbindungen
DE60206034D1 (de) Spritze
DE60216967D1 (de) Substituierte cyclohexanderivate
ATE345337T1 (de) Delta1 -pyrroline
ATA7462001A (de) Radspannwerk

Legal Events

Date Code Title Description
8364 No opposition during term of opposition